Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016144665 - METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS:

1. A compound of Formula (A)

or a pharmaceutically acceptable salt, solvate, clathrate, prodrug, or stereoisomer thereof.

2. A compound of Formula (B)

or a pharmaceutically acceptable salt, solvate, clathrate, prodrug, or stereoisomer thereof.

3. A compound of Formula (C)

or a pharmaceutically acceptable salt, solvate, clathrate, prodrug, or stereoisomer thereof.

4. A compound of Formula (D)

or a pharmaceutically acceptable salt, solvate, clathrate, prodrug, or stereoisomer thereof.

5. A method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1-4.

6. The method of claim 5, further comprising treating said subject with an additional form of therapy for cancer.

7. A method for treating a blood disorder in a subject, comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1-4.

8. The method of claim 7, wherein the blood disorder is at least one of a hemoglobinopathy or a thalassemia.

9. The method of any one of claims 7 or 8, further comprising treating said subject with an additional form of therapy for said blood disorder.

10. The method of claim 5 or 7, further comprising obtaining the compound.

11. The method of claim 5 or 7, wherein the subject is human.

12. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1-4 and at least one pharmaceutically acceptable excipient for treating cancer in a subject.

13. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1-4 and at least one pharmaceutically acceptable excipient for treating a blood disorder in a subject.

14. The pharmaceutical composition of claim 13, wherein the blood disorder is at least one of a hemoglobinopathy or a thalassemia.

15. The pharmaceutical composition of any one of claims 12 or 13, wherein the subject is human.

16. A composition comprising a radiolabelled compound of Formula (A)

or a pharmaceutically acceptable salt, solvate, clathrate, prodrug, or stereoisomer thereof.